SCOTTSDALE, AZ--(Marketwire - August 18, 2008) - ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announced a collaborative relationship with the Biodesign Institute at Arizona State University (ASU), Tempe, Ariz., to evaluate the effectiveness of ImmuneRegen's Viprovex® in boosting the immune response when used as an adjuvant in conjunction with unique plant-derived vaccines against noroviruses (also called Norwalk-like viruses). These viruses are the leading cause of gastrointestinal illness throughout the world, and are often at the root of outbreaks in closed living communities such as nursing homes, cruise ships or prisons. Demonstrating successful adjuvant activity could increase the effectiveness of immunizations, thereby reducing cost per dose and increasing vaccine availability.
